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Graft-versus-host disease (GVHD) can be prevented by Fas-mediated selective depletion of host-sensitized
donor lymphocytes ex vivo. We tested the hypothesis that Fas-mediated depletion of lymphocytes in the
absence of host-speciﬁc antigenic stimulation can alleviate GVHD. Brief exposure (24 hours) of unstimulated
donor lymphocytes to Fas ligand (FasL) ex vivo results in balanced apoptosis of CD8þ and CD4þ subsets with
preferential depletion of CD62L and CD69, increased T regulatory fractions, and sustained responses to
stimulation. This procedure ameliorates weight loss and improves the clinical and histologic score of skin and
gastrointestinal GVHD with and without concurrent transplantation of hematopoietic progenitors and irre-
spective of conditioning-induced tissue injury. Although FasL-resistant donor T cells are less potent effectors
of GVHD, they facilitate hematopoietic progenitor engraftment when infused with or after the graft and retain
the potential to elaborate graft-versus-tumor reactions. These ﬁndings in a preclinical model together with
the known trophic effects of FasL on primitive hematopoietic progenitors suggest that brief ex vivo incubation
of hematopoietic grafts with FasL may improve the outcome and safety of clinical T cellereplete allogeneic
and haploidentical transplants.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION ex vivo procedure involves 3 to 7 days of incubation for
Graft-versus-host disease (GVHD), a severe side effect of
hematopoietic cell transplantation, limits the wide applica-
tion of this therapeutic modality. GVHD is an immune reac-
tionmediated bymature donor Tcells that home to the target
tissues early after transplantation and initiate damaging
inﬂammatory processes in situ [1,2]. Major histocompati-
bility complex disparity leads to dominant alloresponses in
the transplant setting; however, the GVHD reaction is also
stimulated by minor histocompatibility complex and tissue-
speciﬁc antigens, often in the context of normal and
aberrant tissue epitopes exposed by injury inﬂicted by pre-
transplantation conditioning [3]. These immune reactions
against tissue and tumor antigens develop in situ under
variable instructive inﬂuences of host and donor antigen-
presenting cells [4-7]. Although depletion of mature donor
T cells from donor inoculum is largely effective in preventing
this GVHD, complete depletion of T cells from the graft
decreases the efﬁcacy of progenitor engraftment and delays
immune reconstitution.
More subtle approaches to selective depletion of
alloreactive T cells with preservation of graft-facilitating
activity are clearly desirable. One such approach involves
selective depletion of alloreactive T cells by presensitization
of the graft to host antigens inmixed cultures in the presence
of pro-apoptotic signals ex vivo [8-13] and in vivo [14]. Theedgments on page 194.
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12.10.004speciﬁc sensitization of T cells by several rounds of antigen
engagement, a state that concurrently increases their sensi-
tivity to activation-induced cell death (AICD) [15,16]. Further
exposure to T cell mitogens, such as anti-CD3 antibodies, in
these priming cultures results in the depletion of T cell
populations reactive to the host antigens while retaining
the capacity of robust reactivity against third-party
antigens (such as ovalbumin) [9]. Similarly, selective pre-
transplantation depletion of host-primed T cells by Fas cross-
linking preserved graft-versus-tumor (GVT) and antiviral
reactivity [11,12].
In the initial stages of the GVHD reaction, mature donor
T cells trafﬁc according to their repertoire of migration and
adherencemolecules, such as L-selectin and integrins [17,18],
which are differentially expressed and shed by naïve and
activated T cells [19-21]. However, the process of migration is
largely independent of antigen recognition [22,23], when
donor T cells both migrate directly to the target tissues
[24,25] or are initially primed in secondary lymphoid
organs [26-28]. Depletion of phenotypically deﬁned T cell
subsets has been considered as an approach to reduce GVHD
without losing the Tcellemediated graft-supporting activity;
however, the exact nature of GVHD effectors and the
redundant activities of various subsets are not yet deﬁned
[1-4]. For example, depletion of T cells expressing L-selectin
may ameliorate the severity of GVHD [29,30] but at the
same time may negatively impact subsets of T regulatory
cells that act to contain this reaction [31]. Based on
these data, we hypothesized that AICD-based functional
depletion of preactivated T cells may ameliorate the severity
of GVHD without concurrent speciﬁc sensitization to hostTransplantation.
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induction of effector/memory T cells in culture [32,33],
which survive the apoptotic challenge and may contribute to
evolution of GVHD.
In this study, we test the hypothesis that GVHD can be
speciﬁcally suppressed by elimination of naïve, preactivated,
or activated donor T cells from the donor inoculummediated
by exposure to pro-apoptotic signals in the absence of host-
speciﬁc sensitization. We used stringent haploidentical
models of T cellereplete murine bone marrow trans-
plantation to evaluate the impact of selective elimination of
GVHD effectors by Fas-mediated apoptosis in the absence of
speciﬁc T cell priming. We show that this procedure
ameliorates GVHD, preserves GVT reactivity, and retains the
facilitating effect of Tcells on hematopoietic cell engraftment.
MATERIALS AND METHODS
Animal Preparation and Disease Model
Mice used in this study were C57BL/6 (H2Kb, CD45.2), B6.SJL-Ptprca
Pepcb/BoyJ (H2Kb, CD45.1), C57BL/6-TgN(ACTbEGFP)1Osb (Green Fluores-
cent protein [GFP], H2Kb, CD45.2), BALB/c (H2Kd, CD45.2), inbred C57BL/6-
Balb/c F1 chimeras (H2Kb/d, CD45.2), nonobese diabetic (NOD, H2Kg7),
NOD.CB17-Prkdcscid (NOD.SCID, H2Kg7), and B6.Cg-Foxp3tm2Tch transgenic
mice (expressing GFP under control of the FoxP3 promoter) purchased from
Jackson Laboratories (Bar Harbor, ME) and housed in a barrier facility in
accordance with the guidelines of the Institutional Animal Care and Use
Committee.
Recipients were conditioned with sublethal (650 rad) or myeloablative
(850 rad) total body irradiation using an x-ray irradiator (Rad Source Tech-
nologies, Suwanee, GA) at a rate of 106 rad/min [34]. Recipients were grafted
into the lateral tail veinwithwholebonemarrowcells (BMCs), Tcelledepleted
BMCs, or lineage-negative (lin) progenitors suspended in 0.2mL phosphate-
buffered saline. A series of calibration experiments determined that sublethal
GVHD in our models occurred after infusion of 1 to 10  106 splenocytes. In
some experiments, lethal GVHDwas precipitated by intravenous injection of
10 mg lipopolysacharide (LPS, Sigma, St. Louis, MO) [11,13]. In some experi-
ments, the donors were presensitized by two intravenous infusions of 107
allogeneic splenocytes (H2Kd/H2Kb) separated by 3-day intervals [13].
BMC Preparation
Whole BMCs were harvested from the long bones of donors, and low-
density cells were enriched by centrifugation over 1.5 mL Lympholyte-M
(Cedarlane, Ontario, Canada) [34,35]. Negative immunomagnetic selection
was performed by incubation for 45minutes at 4Cwith saturating amounts
of biotinylated anti-mouse monoclonal antibodies, thorough washing with
2% fetal calf serum (Biological Industries, Kibbutz Beit Haemek, Israel), and
incubation with sheep-anti-rat IgG conjugated to M-450 magnetic beads
(Dynal, Lake Success, NY). Cells conjugated to magnetic beads were
precipitated in a magnetic ﬁeld. T cell depletion was performed with
monoclonal antibodies against CD4, CD5, and CD8 from hybridoma cell
cultures (ATCC, Manassas, VA), and lin BMC with monoclonal antibodies
against CD5, MAC-1, GR-1. NK1.1, and B220 (hybridomas) and Ter119
(eBioscience, San Diego, CA). The efﬁciency of lineage and T cell depletion
was reassessed by ﬂow cytometry using cocktails of primary labeled
monoclonal antibodies against the markers listed above.
Lymphocyte Preparation
Spleens and lymph nodes were gently minced on a 40-mM nylon mesh
in HBSS (Biological Industries), and lymphocytes were enriched by centri-
fugation over 1.5 mL Lympholyte-M [13,37]. T cells were further enriched
by elution through a cotton wool column (preferential retention of
B lymphocytes and myeloid cells by differential charge from the eluted T
cells) or collected after immunomagnetic depletion using antibodies against
MAC-1, GR-1. NK1.1, and B220 [36]. The purity of T cell elution was reas-
sessed by ﬂow cytometry using primary labeled monoclonal antibodies
against CD4 and CD8.
Flow Cytometry
Blood, marrow, spleen, and lymph nodes were immunophenotyped
using a Vantage SE ﬂow cytometer (Becton Dickinson, Franklin Lakes, NJ)
and primary labeled antibodies [34,35]. Chimerism was determined in
allogeneic (H2Kb/H2Kd) and haploidentical transplants (H2Kb/H2Kb/d)
using antibodies against H2Kb (clone CTKb, Caltag, Buckingham, UK) and
H2Kd (clone SF-1.1, Pharmingen, Erembodegem, Belgium). GFPþ donor H2Kbsplenocytes (CD45.2, clone 104, eBioscience) were dissociated from the
bone marrow according to minor antigen disparity (CD45.1, clone A20,
eBioscience) grafted into F1 recipients (K2Kb/d, CD45.2) [38]. Cell death
and apoptosis were determined in cells incubated with 5 mg/mL
7-aminoactinomycin-D (Sigma) and Annexin-V (IQ Products, Groningen, the
Netherlands), respectively. T cells were characterized using labeled mono-
clonal antibodies against CD8 (clone 53-6.7), CD4 (clone RM 4-5), CD25
(clone PC61.5), B220 (clone RA3-6B2), CD62L (cloneMEL-14), CD45RB (clone
16A), CD44 (clone 1M7), and CD69 (clone H1.2F3) purchased from BD
Pharmingen and eBioscience.
In Vitro Apoptosis
Cell suspensions were incubated for 24 to 48 hours at 37 in 5% CO2 in
a humidiﬁed incubator in medium and with FLAG-tagged FasL (Axxora,
Lausen, Switzerland) [37]. Splenocytes (5106 cells/mL) were suspended in
MLR medium and BMCs (5  106 cells/mL) were incubated in aMEM sup-
plemented with StemPro Nutrient Supplement (Stem Cell Technologies,
Vancouver, BC), 2 mM L-glutamine, 50 mM 2b-Mercaptoethanol [34,35].
Proliferation Assay
Responders were loaded with 10 mM 5-(and 6-)-carboxyﬂuorescein
diacetate succinimidyl ester (CFSE, Molecular Probes, Eugene, OR) at room
temperature for 7 minutes [35]. For mixed lymphocyte reactions, CFSE-
labeled responders were cocultured with irradiated (3000 rad) stimulators
cells (1:3 ratio) [38]. CFSE dilution was analyzed using ﬂow cytometry by
gating on the live lymphocytes, and proliferation was quantiﬁed using the
ModFit software (Verity Software House, Topsham, ME).
Tumor Cells
Two  106 CT26 murine (H2Kd) colon carcinoma cells (ATCC)
were implanted subcutaneously into the ﬂank of 6- to 8-week-old BALB/c
mice (H2Kd), which were subsequently irradiated (800 rad) and grafted
with 5  106 BMC and 107 splenocytes from allogeneic donors
(H2Kb/H2Kd). Tumor size (mm3) was determined using a caliper according
to (length  width2  .4) [39].
Graft-versus-Host Disease
GVHD was assessed using a semiquantitative clinical scale including (1)
posture (hyperkeratosis of the foot pads), (2) diffuse erythema or dermatitis,
(3) diarrhea, and (4) activity [36]. Weight was monitored as an independent
parameter. GVHD was validated histologically in hematoxylin and eosin
sections of the ear and liver and scored as follows: 0 ¼ no lymphoid inﬁl-
tration, 1 ¼ scarce inﬁltrates, 2 ¼ patchy inﬁltration, 3 ¼ diffuse inﬁltration,
and 4 ¼ severe inﬁltration with deterioration of tissue structure.
Histology
Liver and skin were harvested from mice euthanized by CO2 asphyxia-
tion [13,36]. Tissues were embedded in OCT (Sakura Finetek, Torrance, CA),
frozen in isopentane suspended in liquid nitrogen, sectioned (3 to 6 mm)
with a Cryotome (Thermo Shandon, Cheshire, UK), and stained with
hematoxylin and eosin.
Statistical Analysis
Data are presented as means  standard deviations for each experi-
mental protocol. Results in each experimental group were evaluated for
reproducibility by linear regression of duplicate measurements. Differences
between the experimental protocols were estimated with a post hoc Scheffe
t test, and signiﬁcance was considered at P < .05. Signiﬁcant differences in
survival were analyzed by the Mantle-Cox test.
RESULTS
Selective Depletion of Host-Sensitized Donor T Cells
Prevents Lethal GVHD
It has been demonstrated that ex vivo depletion of host-
presensitized immune cells prevents GVHD after allogeneic
and haploidentical hematopoietic transplants [9,11,12]. We
recapitulated these experiments using an in vivo model of
donor sensitization against host antigens [13] to shorten the
period of exposure to the apoptotic factor as a control to our
experimental setting (Figure 1A). Lymphocytes harvested
from B6 mice (H2Kb) immunized with BALB/c lymphocytes
(H2Kd) displayed increased proliferative responses to H2Kd
stimulators as compared with third-party (H2Kk) antigens
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Figure 1. Fas-mediated elimination of presensitized GVHD effectors. (A) H2Kb donors were immunized twice with 107 allogeneic H2Kd splenocytes at 3-day intervals.
Three days after second immunization, splenocytes (imH2Kb) were cultured in medium and with 50 ng/mL FasL for 24 hours. (B) Splenic lymphocytes of immunized
mice display increased responses to the irradiated (3000 rad) allogeneic antigens (H2Kd) used for immunization as compared with third-party stimulators (H2Kk),
which persist after incubation in medium and are signiﬁcantly suppressed by incubation with FasL, while sustaining responsiveness to third-party stimuli. Prolif-
eration was determined from CFSE dilution and quantiﬁed using the ModFit software (n ¼ 5 individual incubations). (C) Viable lymphocytes (1.5  106) from the
immunized donors were adoptively transferred into sublethally irradiated (650 rad) F1 recipients (H2Kb/H2Kb/d) after ex vivo incubation in medium and with FasL.
Differences in survival were polarized by administration of 10 mg LPS on day þ7 (n ¼ 8 in each group).
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incubation of the responders in control medium. Exposure
to a toxic dose of FasL reduced the responsiveness of
presensitized splenocytes to H2Kd stimulators, without
impairing the responses to third-party H2Kk antigens
(Figure 1B). The responses to third-party antigens were in
fact similar to responses of naïve (nonimmunized) mice to
alloantigens during the same period of coculture. To evaluate
the effects of FasL on the GVHD effector activity, 1.5  106
viable sensitized lymphocytes served as parental donors to
sublethally irradiated (650 rad) haploidentical F1 recipients
(H2Kb/H2Kb/d). Infusion of presensitized lymphocytes
incubated in control medium caused severe GVHD, which
became uniformly lethal after an LPS challenge (Figure 1C).
By contrast, ex vivo incubation of lymphocytes from the
presensitized donors with FasL led to survival of 50% of mice
even after administration of LPS. This in vivo model conﬁrms
that alloantigen-driven lymphocyte stimulation results in
the elaboration of GVHD effectors that can be speciﬁcally
eliminated using proapoptotic agents.
Depletion of Fas-Sensitive Unstimulated T Cells Prevents
Lethal GVHD
In view of the antigen-independent initial donor T cell
migrationandactivation,we reasoned that pretransplantation
exposure of donor lymphocytes to an apoptotic challenge
might be effective in elimination of T cells with GVH reactive
potential. Splenocytes were exposed to FasL ex vivo
(Figure 2A) in the absence of previous or concurrent exposure
to host antigens and without proliferative stimuli [9-12].
Unstimulated T cells exposed to FasL for 24 hours displayed
preserved responses to alloantigens (Figure 2B), similar to
sustained responsiveness of antigen-selective depleted T cells
to third-party antigens (Figure 1B). Adoptive transfer of
1.5  106 viable lymphocytes into sublethally irradiated (650
rad) F1 recipients (H2Kb-GFP/H2Kb/d) did not result in acute
mortality, irrespective of incubation with and without FasL
(Figure 2C). Both measurements of body weight (Figure 2D)
andclinical score (Figure2E) showedreducedseverityof acuteGVHD in recipients of FasL-pretreated lymphocytes. Further
escalation of the numbers of parental lymphocytes resulted in
improved bodyweights and clinical scores after pretreatment
with FasL, indicating that larger numbers of donor T cells are
tolerated after ex vivo exposure to the apoptotic challenge. To
evaluate immune recovery, sublethally irradiated recipients
were phenotyped as early as 1 week after adoptive transfer of
3  106 allogeneic splenocytes. Pretransplantation elimina-
tion of Fas-sensitive immune cells had no signiﬁcant impact
on early immune reconstitution (Figure 2F) phenotypes also
recorded at later times post-transplantation.
Administration of LPS in this high-risk GVHD model of
parent donor to F1 recipients induced acute death in all
recipients of lymphocytes incubated in medium, whereas
70% of recipients of FasL-pretreated lymphocytes survived
(Figure 2C). This polarized survival pattern is consistent with
reduced severity of GVHD inﬂicted by lymphocytes exposed
to the apoptotic challenge as seen in other parameters of the
disease (Figure 2D and E). To assess the differential impact of
LPS, the composition of spleens was evaluated in mice that
survived the LPS challenge for 2 days (Figure 2G). Recipients
of lymphocytes incubated in control medium responded to
LPS by a surge in splenic CD4þ and CD8þ T cells (P < .001),
which was signiﬁcantly reduced in recipients of FasL-
pretreated splenocytes (P < .001). The GVHD-protective
effect of FasL preincubation seemed not to involve genera-
tion of regulatory T cells, because fractional expression of
CD25 and FoxP3 was similar in the spleens of 2-day LPS
survivors after infusion of FasL-treated or control lympho-
cytes (not shown). Taken together, these data demonstrated
that exposure of donor lymphocytes to FasL in the absence of
stimulation by host antigens protects from acute GVHD in
a high-risk parent to F1 hybrid acute GVHD model.
Depletion of Fas-Sensitive Naïve Splenocytes Alleviates
GVHD While Maintaining Immune and Hematopoietic
Reconstitution
To extend the ﬁndings of the GVH-like model to the
transplant setting, the effect of Fas-mediated depletion of
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Figure 2. Fas cross-linking of unstimulated lymphocytes prevents severe GVHD. (A) Naïve H2Kb splenocytes were incubated for 24 hours in medium and with
50 ng/mL FasL. (B) Splenic lymphocytes that survived incubation with FasL retained responses to irradiated (3000 rad) allogeneic stimulators (H2Kd) similar to
lymphocytes incubated in medium (n ¼ 5 independent incubations). (C) After incubation in medium (n ¼ 20) and with FasL (n ¼ 10), 1.5  106 viable lymphocytes
were infused into sublethally irradiated (650 rad) F1 recipients (H2Kb/d), and lethal GVHD was precipitated by 10 mg LPS administered on day þ7. (D) Changes in
body weight and (E) clinical score on day þ7 are shown for recipients of various numbers of semiallogeneic donor lymphocytes (H2Kb/H2Kb/d) preincubated in
medium and with FasL (n ¼ 5-10 in each group). (E) Clinical score on day þ7 after infusion of various numbers of semiallogeneic lymphocytes pretreated in
medium and with FasL (n ¼ 5-10 in each group). (F) Reconstitution of the major splenic lineages at 1 week after adoptive transfer of 3  106 splenocytes pre-
incubated in medium and with FasL into irradiated mice (H2Kb/H2Kb/d): CD4þ and CD8þ T cells, B220þ B lymphocytes and GR-1þ granulocytes (n ¼ 5). (G) Mice
that survived the LPS challenge after infusion of unstimulated lymphocytes preincubated in medium (LPS medium) and with FasL (LPS FasL) were assessed for
changes in splenic CD4þ and CD8þ T cells (n ¼ 5 in each group).
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identical bone marrow transplantation together with donor
lymphocyte infusion. Irradiated (850 rad) F1 recipients that
received 5  106 parental BMCs together with 2  107 sple-
nocytes preincubated in control medium for 24 hours
(H2Kb/H2Kb/d) succumbed to lethal GVHD, whereas incu-
bation with FasL rescued 70% of the mice (P < .005,
Figure 3A). Infusion of smaller numbers (1.5, 3, and 4.5
million) of splenocytes preincubated in control medium for
24 hours survived and manifested signiﬁcant 10% to 15%
weight loss (Figure 3B) and severe clinical GVHD score
(Figure 3C), conﬁrmed by high-grade histologic disease score
in the liver and ear (Figure 3D). Overall, weight loss did notcorrelate with increasing splenocyte dose, although skin
GVHD tended to worsen after infusion of higher doses of
splenocytes. Transplantation of unstimulated splenocytes
preincubated with FasL blunted weight loss (P < .005),
decreased the clinical GVHD score (P < .005), and reduced
lymphocytic inﬁltrates in the affected target organs
(P < .005). Residual low-grade GVHD activity did, however,
persist after infusion of >3  106 FasL-pretreated haplo-
identical splenocytes.
To determine how depletion of Fas-sensitive donor
splenocytes affects immunohematopoietic reconstitution
after transplantation, hosts were assessed for chimerism,
survival of the grafted donor lymphocytes, and immune
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Figure 3. Elimination of Fas-sensitive naïve immune cells in haploidentical transplants. F1 recipients (H2Kb/d) irradiated at 850 rad were grafted with 5  106 T
celledepleted BMCs (H2Kb, CD45.1) and various numbers of viable donor lymphocytes (H2Kb, CD45.2, GFP) as shown in Figure 2A. (A) Survival of mice infused with
2  107 donor splenocytes with and without pre-exposure to FasL (n ¼ 10 in each group). (B) Weight loss was blunted by donor lymphocyte pretreatment with FasL
(n ¼ 8 in each group). (C) Clinical score with incidence of gastrointestinal involvement (GI) at 3 weeks after transplantationwere reduced in recipients of lymphocytes
preincubated with FasL for 48 hours rather than medium (n ¼ 8 in each group). (D) Histologic evaluation of ear skin and liver in recipients of 3  106 splenocytes
incubated in medium and with FasL (n ¼ 5). (E) Donor chimerism in peripheral blood (n ¼ 5). Representative plots are shown for reduced donor (H2Kb) and increased
host (H2Kb/d) chimerism in recipients of 4.5106 lymphocytes preincubated in medium as comparedwith cells preincubated with FasL. (F) Grafted donor lymphocytes
(3 106 CD45.2þGFPþ) make a small contribution to spleen cellularity (n¼ 5), which largely originates from the BMCs (CD45.1þGFP). (G) The reconstituted spleens of
recipients graftedwith 3106 lymphocytes preincubated inmedium andwith FasL display similar responses against third-party antigens (H2Kk, upper panels) and are
unresponsive to the host (H2Kd, lower panels). Proliferation was determined from CFSE dilution and quantiﬁed with the ModFit software (n ¼ 4).
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Figure 4. Impact of Fas-mediated depletion on engraftment, donor lymphocyte infusion, and GVT. (A-C) Irradiated (800 rad) H2Kd recipients were grafted with
allogeneic (H2Kb) BMCs, and chimerism was determined in peripheral blood. (A) Peripheral blood chimerism at 3 weeks after simultaneous transplantation of 106
lineage-negative allogeneic (H2Kb) BMCs (n ¼ 7) and 106 F1 lymphocytes (H2Kb/d) preincubated in medium (n ¼ 5) and with FasL (n ¼ 6) for 24 hours. (B) Peripheral
blood chimerism at 6 weeks after transplantation of 2  106 allogeneic (H2Kb) lineage-negative BMCs (n ¼ 6) and with additional donor lymphocyte infusion (DLI) on
day þ10: 106 allogeneic lymphocytes (H2Kb) preincubated in medium and with FasL for 24 hours (n ¼ 5). (C) Peripheral blood chimerism at 3 weeks post-
transplantation of 2  106 allogeneic (H2Kb) whole BMCs, after preincubation of the whole graft for 24 hours in medium and with FasL (n ¼ 6). (D) CT26 murine
colon carcinoma was implanted subcutaneously in congenic H2Kd mice, and after 3 days they were irradiated (800 rad) and reconstituted with 5  106 BMCs alone
(BMC, n ¼ 8) and with 107 splenocytes from 5-week-old allogeneic (H2Kb) donors, preincubated for 24 hours in medium (n ¼ 9) and with FasL (n ¼ 8) before
transplantation.
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that severe GVHD suppresses engraftment of hematopoietic
progenitors and decreases the levels of donor chimerism
[40,41]. In our model, recipients of the highest dose
(4.5  106) of unmanipulated donor splenocytes pre-
incubated in control medium displayed decreased levels of
chimerism at 3 weeks (Figure 3E) and 6 weeks
posttransplantation (not shown), whereas pretreatment of
donor lymphocytes with FasL abrogated this graft-
suppressive effect of severe GVHD.
Because the mature lymphocytes infused at the time of
transplantation compete with lymphocytes generated by the
bone marrow graft for peripheral homeostatic expansion
[39], we were interested in the impact that FasL-treated
lymphocyte infusions would have on lymphoid reconstitu-
tion. We used GFP and minor CD45 antigen disparity to
differentiate between infused splenocytes (GFPþCD45.2þ)
and BMC graft-derived T cells (GFPCD45.1þ). Despite the
fact that F1 recipients do not reject parental immune cells,
few of the infused splenocytes (H2KbCD45.2þGFPþ) were
detected in peripheral lymphoid organs of the recipients at 3
weeks posttransplantation, whether or not they had been
incubated with FasL or control medium (Figure 3F). Quali-
tatively, recipients of control and FasL-pretreated spleno-
cytes displayed unresponsiveness to both donor and host
antigens as expected for chimeric mice and responded
equally well to third-party (H2Kk) antigens (Figure 3G).
Therefore, ex vivo treatment of lymphocytes with FasL seemsto effect neither quantitative nor functional immune recon-
stitution after transplantation. These data are consistent
with the demonstration that amelioration of GVHD enhances
engraftment and immunohematopoietic reconstitution
[40,41].
Depletion of Fas-Sensitive Splenocytes Does Not Impair
Facilitation of Hematopoietic Cell Engraftment
Bulk T cell depletion of hematopoietic grafts removes
engraftment-facilitating cells, requiring a compensatory
infusion of large doses of stem cells [38]. To further explore
the effect of FasL incubation on graft function, irradiated
H2Kd mice (800 rad) were grafted with 106 viable H2Kb lin
BMC and 106 viable F1 lymphocytes (H2Kb/d). The F1 hybrid
lymphocytes were used to dissociate between facilitation of
engraftment from the GVHD, because these lymphocytes are
anergic to host antigens and are devoid of GVH reactivity
[39]. In this experiment, only lymphocytes were pre-exposed
to FasL, because Fas cross-linking augments progenitor
engraftment [34]. Engraftment was signiﬁcantly improved
by adoptive transfer of F1 lymphocytes, irrespective of pre-
incubation in medium or FasL (Figure 4A), demonstrating
that depletion of Fas-sensitive splenocytes does not impair
their capacity to facilitate progenitor engraftment. We also
assessed posttransplantation donor lymphocyte infusion, an
effective approach to enhance donor chimerism and boost
GVT activity, which has lesser GVHD activity as compared
with infusion of the lymphocytes at the time of progenitor
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rism was attained when donor lymphocytes preincubated in
medium and with FasL were administered 10 days after
transplantation of lin progenitors (Figure 4B). Because
hematopoietic progenitors are largely insensitive to Fas-
mediated apoptotic signals [34,35], it is conceivable that
exposure of the entire graft to the apoptotic challenge will
only attenuate GVHD but not engraftment. Transplantation
of 2  106 allogeneic (H2Kb/H2Kd) whole BMCs into irra-
diated hosts (800 rad) conﬁrmed that pretransplantation
exposure of the bulk graft to FasL does not impair engraft-
ment (Figure 4C).
Apoptotic Challenge Alleviates GVHD without Impairing
GVT
The overall success of stem cell transplantation per-
formed for the treatment of malignant diseases depends on
GVT effects. Bulk depletion of T cells (either ex vivo or by
administration of potent in vivo immune suppression) can
blunt the GVT reaction and increase posttransplantation
relapse rates in a variety of clinical situations [44]. We
investigated whether FasL incubations abrogated GVT in
parallel to its salutary effect on GVHD in our model of
transplantation. CT26 murine colon carcinoma cells (H2Kd)
were implanted in congenic BALB/c mice (H2Kd), which were
irradiated and grafted with 5  106 allogeneic BMCs and 107
splenocytes (H2Kb/H2Kd). Transplantation of splenocytes
preincubated in medium and with FasL for 24 hours slowed
the growth of the tumor implants (Figure 4D), conﬁrming
that incubation with FasL preserves lymphocyte-mediated
GVT reactivity. Recipients of this dose of donor splenocytes
survived and displayed signs of low-grade GVHD. This
ﬁnding is consistent with the contention that GVHD is not an
obligate handmaiden of GVT effects [39].
Characteristics of Apoptotic and Viable Cells Exposed to
FasL
The impact of the apoptotic challenge on the composition
of unstimulated splenocytes was assessed in a series of
in vitro experiments. Measurements were performed in bulk
preparations of splenocytes, considering that apoptosis is
dominated by the cytokine environment and interactions
between various cell types [45]. Exposure of ustimulated
splenocytes to FasL resulted in balanced spontaneous and
Fas-mediated apoptosis of both CD4þ and CD8þ subsets at
both incubation times (Figure 5A). Within the CD4þ subset,
cells with highest levels of CD25 expression are less sensitive
to Fas cross-linking as compared with CD25/low cells
(Figure 5B), suggesting relative insensitivity of putative
regulatory T cells (Treg) to apoptosis. This possibility was
validated by the reduced susceptibility to spontaneous
apoptosis of CD4þFoxP3þ T cells from FoxP3-GFP transgenes,
which are induced into apoptosis, however, by Fas cross-
linking with an overall survival similar to CD4þCD25high
cells (Figure 5B). These variations in fractional apoptosis in
reference to CD25 expression are not caused by differential
proliferation of viable cells (Figure 5C), despite the fact that
unlike puriﬁed subsets, CD25þ Treg do not display prolifera-
tive anergy in mixed splenocyte cultures [45]. Notably, both
apoptosis (Figure 5A) and proliferation (Figure 5C) were
more accentuated during the ﬁrst 24 hours of incubation
than during the subsequent period. Taken together, these
data document balanced depletion of T cell subsets by Fas
cross-linking in unstimulated splenocyte preparations, with
modest sparing of Treg phenotypes.Further assessment of the phenotype of viable cells
indicate that exposure of unstimulated lymphocytes to FasL
induces apoptosis in T cells bearing the activation marker
CD69 (Figure 5D). Among adhesion molecules involved in
homing, enhanced sensitivity to Fas cross-linking was
observed in CD4þ T cells expressing L-selectin, in the pres-
ence of insigniﬁcant impact on fractional expression of a4b1
integrin (VLA-4). Exposure to FasL also causes modest down-
regulation of the activation and effector/memory T cell
markers, as determined from decreased mean ﬂuorescence
intensities: CD5RB decreased from 2.2 to 1.9 and CD44
decreased from 2.4 to 2. Because L-selectin and integrins are
important in migration of GVHD effectors [17-21,29-31], we
assessed possible impairment of T cell homing mediated by
Fas cross-linking. Cells pre-exposed to medium and to FasL
displayed similar afﬁnity to the spleen and lymph nodes of
irradiated recipients (Figure 5E), indicating that decreased
CD62L expression is not the main mechanism of reduced
GVHD. Effective migration of lymphocytes to the lymphoid
organs after ex vivo exposure to FasL indicates that the
apoptotic challenge selectively modulates functional char-
acteristics of viable T cells.
DISCUSSION
Presentation of antigens in conjunction with apoptotic
signals eliminates activated cells [46] and has been used
successfully for antigen-speciﬁc abrogation of immune
responses in vivo [38,47-50]. This simulation of physiologic
AICD has also been implemented for ex vivo elimination of
activated cells from donors with a pre-existing autoimmune
disease such as diabetes [51] and selective depletion of host-
sensitized donor Tcells [8,9,11,12]. Clinical implementation of
this method of allosensitization and depletion ex vivo is
cumbersome and involves mixed lymphocyte culture of the
graft with cells that present the host alloantigen. In this study
we demonstrate that brief exposure of naïve donor lympho-
cytes to an apoptotic signal ex vivo, even in the absence of
antigenic stimulation of any kind, abrogates lethal GVHD in
stringent models of T cellereplete haploidentical bone
marrow transplants. Despite effective amelioration of GVHD
by elimination of Fas-sensitive unstimulated T cells, facilita-
tion of progenitor engraftment, immune reconstitution, and
reactivity to third-party and tumor antigens were preserved.
An initial experimental observation showed that Fas-
mediated depletion of host-naïve donor immune cells has
the same and even superior capacity to ameliorate GVHD as
compared with selective depletion of host-sensitized donor
T cells. Our current data suggest that elimination of
apoptosis-prone T cells without host sensitization reduces
the propensity of GVHD effectors within the donor inoculum
under all the tested experimental conditions and irrespective
of simultaneous transplantation of hematopoietic progeni-
tors. The most prominent feature associated with superior
survival and reduced GVHD severity was reduced respon-
siveness of both CD4þ and CD8þ Tcell subsets to the cytokine
stimulation induced by LPS. This behavior was observed at an
early time point when the dominant fraction of T cells orig-
inate from the donor graft, before subsequent transition to
dominant reconstitution by the bone marrow progeny [39].
These data are intrinsically consistent, as apoptosis by Fas
cross-linking affects preferentially activated T cells sensitive
to AICD, whereas the surviving T cells are predominantly
naïve and hence are expected to display reduced respon-
siveness to cytokine stimulation. Therefore, we favor the
possibility that the main mechanism of reduced GVH
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Figure 5. The impact of ex vivo Fas cross-linking on unstimulated splenocytes. Measurements of apoptosis and proliferation were performed by gating on the
appropriate subsets within bulk splenocyte preparations. (A) Incubationwith FasL induces apoptosis in splenic CD4þ and CD8þ T cells from naïve H2Kb mice (n ¼ 5-8),
superposed on spontaneous apoptosis in medium. (B) Differential sensitivity to spontaneous (medium) and FasL-induced apoptosis of CD4þ T cell subsets in reference
to the intensity of CD25 expression (n ¼ 4-8). Apoptosis of CD4þFoxP3þ T cells was measured in splenocytes from transgenes expressing GFP under control of the
FoxP3 promoter. (C) The CD25þ subset of CD4þ T cells cycles at slower rates than the CD25 subset, and both are slightly slowed by exposure to FasL (n ¼ 4-7), as
determined from CFSE dilution. (D) Fractional expression of CD25, the activation marker CD69, and adhesion molecules L-selectin (CD62L) and integrin (VLA-4) in
gated CD4þ T cells after incubation in medium and with FasL for 24 hours. The right panel shows representative histograms of CD69 (upper) and CD62L (lower)
expression after incubation in medium and with FasL. (E) GFPþ lymphocytes (H2Kb) preincubated with medium and FasL home to the mesenteric lymph nodes of
sublethally irradiated (650 rad) F1 recipients (H2Kb/d), as determined at 24 hours after transplantation.
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speciﬁc antigen stimulation involves a decline in frequency
of preactivated donor T cells with effector potential.We investigated several possible mechanisms by which
infusion of unstimulated cells exposed to FasL-induced
apoptosis might ameliorate GVHD while preserving other
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lymph nodes [18], either by direct migration to the target
tissues [24,25] or after priming in secondary lymphoid organs
[26,27], which are redundant modes of activation of GVHD
effectors [28]. Decreased fractions of cells expressing CD62L
might reduce the migration of T cells to the target tissues,
ameliorating the severity of GVHD [17,29]. However, we
found that Fas-resistant unstimulated donor Tcells navigated
effectively despite fractional depletion of cells expressing L-
selectin, at low levels of a4b1-integrin expression. Our results
are consistent with a modest impact of modulation of L-
selectin levels on GVHD effector frequency and activity
[18,21] and corroborate the concept that lymphocyte traf-
ﬁcking is independent of antigen recognition [22,23].
We also attempted to assess the modulation of donor T
cell capacity to elicit GVHD by phenotypic characterization of
the Fas-resistant T cells. We found relatively small variations
in the propensity of the CD45RB and CD44 expression after
the apoptotic challenge applied in the absence of host-
speciﬁc stimulation, corresponding to phenotypes that var-
iably affect GVHD severity [3,18,52-55]. The superior survival
of regulatory T cells under apoptotic signaling by Fas cross-
linking is an additional beneﬁcial mechanism that has the
capacity to ameliorate GVHD [30,31,56,57]. Although FoxP3þ
Treg fromGFP-transgenic mice showed reduced susceptibility
to spontaneous apoptosis as compared with CD25þ Treg in
culture, they were excessively sensitive to Fas cross-
linking [37], resulting in similar levels of receptor-mediated
death of both Treg phenotypes. However, both Treg subsets
were less sensitive to the apoptotic challenge that naïve/
effector T cells, and their ampliﬁcation under conditions
of lymphopenia-induced proliferation in vivo [13] is consis-
tent with reduced GVHD severity after the apoptotic
challenge.
A small but signiﬁcant superior survival of recipients of
naïve T cells as compared with recipients of cells from host-
immunized mice after brief exposure to FasL was evident
upon immune stimulation with LPS. We used a model of
repeated immunization of the donor mice with host antigens
in vivo followed by a brief apoptotic challenge in vitro [13],
whereas other studies used extended ex vivo coculture of
donor responders to host stimulators in the presence of
apoptotic signals [8-12]. In bothmodels of in vivo and ex vivo
sensitization of donor T cells, the time of exposure is an
important parameter due to possible evolution of effector/
memory phenotypes. Extended periods of culture time are
essentially required to allow repeated rounds of antigen-
speciﬁc sensitization [32,33], whereas induction of Fas-
mediated apoptosis is efﬁciently achieved within a very
short period of time [15,16]. Although our data concur with
effective depletion of sensitized GVHD effectors by AICD
ex vivo [8-13], extended exposure to antigens for several
days allows transition of some activated lymphocytes to
primed/memory T cell phenotypes [32,33]. This latter
lymphocyte population is relatively resistant to Fas cross-
linking [58-60], in part due to up-regulation of FLICE Inhib-
itory Protein [61] and low levels of caspase-3 [62], which
has been overcome by interleukin-2 receptoremediated
introduction of caspase-3 into the reactive cells [13]. Acqui-
sition of apoptosis-resistant phenotypes of host-sensitized T
cells during extended ex vivo culture may predispose to
subsequent acute or chronic GVHD [18,52-55]. Effector/
memory cells per se are less effective mediators of GVHD as
compared with naïve T cells [63-65], but their continued
presence leads to persistent GVH reactivity [52].The apoptotic challenge that reduced GVH reactivity of
donor T cells did not affect two signiﬁcant functions. In the
context of oncologic transplants, we demonstrate persistent
GVT reactivity after depletion of Fas-sensitive unstimulated
donor T cells under conditions of radiation-induced lym-
phopenia. As demonstrated in prior reports of selective
ex vivo priming of the donor lymphocytes to host antigens
[9,11], GVT reactions are dissociated from and do not require
concurrent GVH reactivity after mismatched immunohema-
topoietic reconstitution [36,42,43]. The other signiﬁcant
mechanism is preservation of the facilitating effect of T cells
on hematopoietic cell engraftment after ex vivo Fas cross-
linking, which is a signiﬁcant advantage of our experi-
mental approach as compared with clinical immunologic
methods for indiscriminate Tcell elimination [1,2]. One of the
physiologic roles of donor T cells is facilitation and potenti-
ation of seeding by interaction with bone marrow stroma in
initial stages of hematopoietic stem and progenitor cells
engraftment [66,67], which is partially mediated by stromal
Fas cross-linking through interactionwith the cognate ligand
expressed in donor cells [38]. Despite induction of apoptosis
in signiﬁcant fractions of CD4þ and CD8þ T cells by Fas cross-
linking, superior engraftment achieved by add-back of
untreated and FasL-depleted T cells provides direct evidence
of preserved facilitating effect in our model. This mechanism
was preserved after elimination of apoptosis-sensitive T cells
because cytolytic activity is not a prerequisite of the
facilitation phenomenon [40,41,68]. This is a distinct mech-
anism from the cytolytic activity of donor T cells that
ameliorate host versus graft resistance by elimination of
residual host immune cells, which can be reinforced by
ectopic expression of FasL [38,47-50].
The proposed approach ameliorates GVHD at doses
exceeding 6  107 T cells/kg and has several advantages over
current procedures and ex vivo depletion of host-sensitized T
cells. In variance from indiscriminate phenotypic elimination
of T cells from donor inoculum, selective elimination of
Fas-sensitive cells leaves behind subsets that facilitate
progenitor engraftment and may augment GVT immunity.
Other methods for selective ex vivo depletion of host-
sensitized T cells [8-12] rely on extensive manipulation of
the donor inoculum before infusion and require separation
of the hematopoietic progenitors when cytotoxic agents
are used to deplete the donor lymphocytes [69]. In contrast,
the proposed approach does not require manipulation of
the graft, as hematopoietic progenitors are inherently
insensitive to Fas-mediated apoptosis as demonstrated in
mice [34,35] and validated in human umbilical cord blood
and mobilized peripheral blood cells (K. Mizrahi, unpub-
lished data). Furthermore, protection from GVHD by Fas-
mediated apoptosis of donor lymphocytes actually
enhances progenitor engraftment because signaling via Fas,
tumor necrosis factor-a, and tumor necrosis factor-related
apoptosis-inducing ligand receptors is associated with
predominant tropic effects in these cells [34,70,71]. Inherent
resistance of the progenitors to Fas-mediated apoptosis can
be exploited to prevent GVHD through bulk culture of
unfractionated donor cells in FasL-containing medium,
obviating the requirement of progenitor storage during T cell
manipulation.
In summary, we described a simple and effective method
for selective depletion of GVHD effector lymphocytes using
FasL in the absence of ex vivo sensitization of donor T cells to
host in a preclinical model. Duration of the ex vivo incuba-
tion correlates positively with the numbers of donor
N. Askenasy et al. / Biol Blood Marrow Transplant 19 (2013) 185e195194lymphocytes that can be grafted without causing high-grade
GVHD; however, signiﬁcant protection from GVHD can also
be achieved by brief incubations of the entire graft that does
not impair the engraftment of hematopoietic stem cells. The
proposed approach eliminates severe GVHD in T cellereplete
transplants, preserves the tumorlytic activity of mismatched
donor T cells, maintains T cell reactivity to third-party anti-
gens, and, most important, facilitates hematopoietic stem
cell engraftment.
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